Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

  • Idiopathic Pulmonary Fibrosis
Trial Status:

Completed

This trial runs in
Countries
  • Greece
Trial Identifier:

NCT03115619 ML39259

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).

      Hoffmann-La Roche Sponsor
      NCT03115619 , ML39259 Trial Identifier
      Pirfenidone Treatments
      Idiopathic Pulmonary Fibrosis Condition
      Official Title

      A Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon Study

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Adult participants for whom pirfenidone has already been prescribed for IPF no more than 4 weeks prior to enrollment, according to their physicians' clinical decision and the terms in the SmPC
      Exclusion Criteria
      • Participants who are participating in an interventional study or have received any investigational agent in the past 4 weeks

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now